Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03344250 · ClinicalTrials.gov registry record · Phase 1
Phase I EGFR BATs in Newly Diagnosed Glioblastoma
A Phase 1 study, sponsored by University of Virginia.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT03344250 is a Phase 1 study that has completed, run by University of Virginia. The registered enrollment target is 16 participants.
The verdict
NCT03344250, a Phase 1 study, has completed, sponsored by University of Virginia.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
This is a phase I trial using EGFR Bi-armed Activated T-cells (BATs) in combination with standard of care temozolomide (TMZ) and radiation (RT) in patients with glioblastoma (GBM). The purpose of the study is to determine a safe dose of EGFR BATs when given with standard of care therapy.
Interventions
- DRUG EGFR BATs with TMZ following SOC RT/TMZ
- DRUG Weekly EGFR BATs following SOC RT/TMZ
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2018-03-01 |
| Est. Completion | 2023-05-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03344250
The ClinicalTrials.gov registry entry for NCT03344250 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Virginia, which has 449 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which EGFR BATs with TMZ following SOC RT/TMZ is the first listed.
NCT03344250 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03344250 about?
NCT03344250 is a clinical study titled "Phase I EGFR BATs in Newly Diagnosed Glioblastoma". This is a phase I trial using EGFR Bi-armed Activated T-cells (BATs) in combination with standard of care temozolomide (TMZ) and radiation (RT) in patients with glioblastoma (GBM). The purpose of the study is to determine a safe dose of EGFR BATs when given with standard of care therapy.
What is the current status of trial NCT03344250?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2018-03-01. Estimated completion is 2023-05-08.
What interventions are being tested in trial NCT03344250?
The interventions under investigation include: EGFR BATs with TMZ following SOC RT/TMZ (DRUG), Weekly EGFR BATs following SOC RT/TMZ (DRUG).
Who is sponsoring clinical trial NCT03344250?
This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.